title: Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.
abstract: Chronic myeloid leukaemia in children and young people is a relatively rare form of leukaemia that shows increased incidence with age and some evidence suggests that the molecular basis differs from that in adults. Significant advances in targeted therapy with the development and use in children of tyrosine kinase inhibitors and the ability to monitor and understand the prognostic significance of minimal residual disease by standardized molecular techniques has shifted the management of this condition from bone marrow transplantation as the main therapeutic modality to individualized treatment for each patient based on achieving specific milestones. The physiological changes occurring during childhood, particularly those affecting growth and development and the long-term use of treatment, pose specific challenges in this age group, which we are only beginning to understand.
authors: Paediatrics Department, Saint Mary Hospital, London, UK.
authors: Josu
authors: J
authors: de la Fuente
authors: André
authors: A
authors: Baruchel
authors: Andrea
authors: A
authors: Biondi
authors: Eveline
authors: E
authors: de Bont
authors: Marie-Françoise
authors: MF
authors: Dresse
authors: Meinolf
authors: M
authors: Suttorp
authors: Frédéric
authors: F
authors: Millot
mesh_terms: D000293:Adolescent; D000465:Algorithms; D002648:Child; D002675:Child, Preschool; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry / Q000235:genetics; D019983:Guideline Adherence; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D055118:Medication Adherence; D009154:Mutation; D011247:Pregnancy; D054730:Protein Interaction Domains and Motifs / Q000235:genetics
chemical_list: D016044:Fusion Proteins, bcr-abl
keywords: BCR-ABL1; children; chronic myeloid leukaemia; stem cell transplantation; tyrosine kinase inhibitor